Scarica l'app Stockscreener
48.80
5.33%
-2.788
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$51.59
Aprire:
$50.77
Volume 24 ore:
2.18M
Relative Volume:
0.31
Capitalizzazione di mercato:
$19.34B
Reddito:
$2.23B
Utile/perdita netta:
$-3.19B
Rapporto P/E:
-5.9908
EPS:
-8.1462
Flusso di cassa netto:
$-1.60B
1 W Prestazione:
+3.50%
1M Prestazione:
+4.56%
6M Prestazione:
+76.32%
1 anno Prestazione:
+86.98%
Intervallo 1D:
$48.40
$51.53
Intervallo di 1 settimana:
$43.90
$51.90
Portata 52W:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
48.74 | 19.47B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
447.55 | 108.72B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.41 | 64.89B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.78 | 50.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.98 | 39.06B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
152.01 | 33.16B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna gets good news as it searches for life after Covid - Yahoo Finance Singapore
Why Is Moderna (MRNA) Stock Rocketing Higher Today - TradingView
Broadcom’s Guidance Miss Exposes the Fragility of the AI Trade - Investing.com
[144] Moderna, Inc. SEC Filing - Stock Titan
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Future Challenges - GuruFocus
Moderna Stock: Is MRNA Outperforming the Health Care Sector? - Yahoo Finance
Moderna Inc. stock (US60770K1034): EMA committee backs new RSV vaccine as shares bounce on Nasdaq - AD HOC NEWS
Moderna (MRNA) Climbs 7.5% Ahead of Next Week’s Key Updates - Insider Monkey
Moderna rallies on renewed optimism around its Merck-partnered melanoma vaccine program - Quiver Quantitative
MRNA Stock Quote Price and Forecast - CNN
Moderna (MRNA) CFO exercises 2,475 RSUs, 1,197 shares withheld for taxes - Stock Titan
Moderna (MRNA) CLO converts RSUs into stock while 1,047 shares withheld for taxes - Stock Titan
Moderna (MRNA) president exercises RSUs, reports tax share withholding - Stock Titan
Moderna (NASDAQ:MRNA) Trading 8.1% HigherShould You Buy? - MarketBeat
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion - Investing News Network
HEALTH ROUNDS-Radiation-emitting implant improves outcomes after brain cancer surgery - marketscreener.com
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026 - Yahoo Finance
Moderna Launches Moderna Direct with “eCommerce Powered by FFF Enterprises™” - Yahoo Finance
Moderna CEPI Ebola Vaccine Work Highlights Broader Infectious Disease Ambitions - Yahoo Finance
Moderna to Present at Upcoming Conference in June 2026 - Investing News Network
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus - Zacks Investment Research
UBS Lifts Valuation On Moderna, Inc. (MRNA) Ahead of Key Pipeline Catalysts - Insider Monkey
Biotech Movers: Moderna, Iovance, ALHC, SMMT in Focus - Gotrade
ASCO: Moderna’s mRNA-based melanoma vaccine shows ‘encouraging’ 5-year survival - BioSpace
Moderna, Inc. $MRNA Shares Acquired by Lingotto Investment Management LLP - MarketBeat
Moderna and other groups get $60mln to develop Ebola vaccine - ZAWYA
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus - Black Hills Pioneer
Moderna, Inc. $MRNA Holdings Lowered by Geode Capital Management LLC - MarketBeat
AXQ Capital LP Purchases 39,835 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna and other groups get $60 million to develop Ebola vaccine By Reuters - Investing.com
Drugmaker Moderna, other groups get $60 mln to develop Ebola vaccine - Yahoo Finance UK
Moderna, Inc. (MRNA) Discusses Intismeran mRNA Immunotherapy and Phase II KEYNOTE-942 Oncology DataSlideshow (NASDAQ:MRNA) 2026-06-01 - Seeking Alpha
Why (MRNA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Moderna Tells Fed. Circ. US Must Face COVID Vax Patent Case - Law360
Moderna and other groups get $60 million to develop Ebola vaccine - Reuters
Moderna (MRNA) and Merck (MRK) Report Promising Results for Canc - GuruFocus
Moderna gets $50M investment for Ebola vaccine candidate - Yahoo
Moderna and other groups get US$60 million to develop Ebola vaccine - CP24
Moderna Reports Strong 5-Year Cancer Vaccine Data, Expands CEPI Partnership; Stock Falls - Benzinga
Cambridge drugmaker Moderna joins the Ebola vaccine race - NBC Boston
Moderna joins race for Ebola vaccine as Bundibugyo strain spreads in Africa - The Business Journals
Moderna and CEPI expand collab to include Bundibugyo ebolavirus vaccine - The Pharma Letter
Moderna partners with CEPI on Ebola vaccine efforts amid outbreak in Africa - BioSpace
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting - ACCESS Newswire
Moderna Joins Global Initiative to Advance Vaccine Candidate for Bundibugyo Ebola Virus (MRNA) - Yahoo Finance
Moderna receives $50 million from CEPI for Bundibugyo Ebola vaccine - StreetInsider
Moderna (MRNA) Expands Vaccine Collaboration to Combat Bundibugy - GuruFocus
Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine - Yahoo! Finance Canada
Moderna, Inc. (MRNA) Stock Analysis: Evaluating a Biotech Powerhouse with a -8.46% Potential Downside - DirectorsTalk Interviews
Moderna, Inc. $MRNA Position Reduced by Legal & General Group Plc - MarketBeat
Moderna backs new Ebola vaccine as CEPI commits up to $50M - Stock Titan
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.12%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):